BRAF and lung cancer: We confirm this observation and in addition show that also in SQCC PIK3CA mutations co-occur frequently with driver mutations namely affecting DDR2, KRAS, EGFR, BRAF, HRAS, NFE2L2, CTNNB1, MET, and STK11, beside amplifications of FGFR1 and HER2 and gatekeeper mutations within TP53. Thus, in analogy to the missing specific phenotypic characteristics as described above, these genotype analyses do not suggest a distinct genetic profile of PIK3CA mutated lung cancer neither in the AD nor in the SQCC subgroup.